TMPRSS2 and COVID-19: Notably, the previous observation that ARIs (such as enzalutamide) may inhibit the expression of TMPRSS2 in prostate cancer cells (the originating preclinical findings supporting the exploration of ADT and ARI in COVID-19) may not be relevant in pulmonary tissue, which is an anatomic site very relevant to the development of complications from SARS-CoV-2.29 Baratchian et al30 also found no evidence for increased TMPRSS2 expression in the lungs of male vs female patients or mice and an inability for treatment with enzalutamide to decrease pulmonary TMPRSS2 levels.